Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment ConferenceUnusual Whales·Sep 1 at 08:16 PMANAB-1.15%GSK-1.93%
AnaptysBio-Tesaro trial heads to post-trial briefs, argument set for Oct. 20PUBT·Jul 30 at 08:32 PMANAB-1.15%GSK-1.93%
Buy Rating Reaffirmed on Litigation Clarity and Asset Value; $95 Price Target MaintainedTip Ranks·Jul 21 at 07:23 PMANAB-1.15%
Is AnaptysBio (ANAB) Undervalued As Russell Index Deletions Reshape Trading Flows?Simplywall·Jul 6 at 04:06 PMANAB-1.15%
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus?Simplywall·Jun 30 at 03:51 PMANAB-1.15%
AnaptysBio subleases 45,057 sq ft San Diego office space to First Tracks BiotherapeuticsPUBT·Jun 22 at 08:06 PMTRAX-4.82%ANAB-1.15%
AnaptysBio posts Form 8937 on tax treatment of First Tracks spin-off dividendTradingView·May 29 at 08:23 PMANAB-1.15%TRAX-4.82%
Assessing AnaptysBio (ANAB) Valuation After Strong Recent Share Price GainsSimplywall·May 27 at 05:31 PMANAB-1.15%
AnaptysBio (NASDAQ:ANAB) Trading Down 7.7% After Earnings MissMarket Beat·May 13 at 02:11 PMANAB-1.15%
Anaptysbio | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 25.56 MEarnings Watch·May 12 at 08:31 PMANAB-1.15%
Anaptysbio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 25.56 MEarnings Watch·May 12 at 08:31 PMANAB-1.15%
